NMRA
Neumora Therapeutics Inc.
$3.02
+$0.09(+3.07%)
60
Overall
60
Value
91
Tech
31
Quality
Market Cap
$419.44M
Volume
4.58M
52W Range
$0.61 - $14.09
Target Price
$7.00
Order:
Income Statement
| Metric | Trend | Chart | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|
| OPERATING EXPENSES | |||||
| Operating Expenses | $135.9M | $252.1M | $263.5M | ||
| Research & Development | $104.7M | $142.7M | $200.9M | ||
| Research Expense | $104.7M | $142.7M | $200.9M | ||
| Selling, General & Administrative | $31.1M | $45.5M | $62.5M | ||
| General & Administrative Expenses | $31.1M | $45.5M | $62.5M | ||
| Salaries & Wages | -- | -- | $40.0M | ||
| Depreciation & Amortization | -- | $700.0K | $600.0K | ||
| Depreciation & Amortization | -- | -- | $600.0K | ||
| Other Operating Expenses | -- | -- | $-1.8M | ||
| OPERATING INCOME | |||||
| Operating income | $-135.9M | $-252.1M | $-263.5M | ||
| EBITDA | -- | $-251.4M | $-248.7M | ||
| NON-OPERATING ITEMS | |||||
| Intinc | $4.6M | $16.6M | $19.9M | ||
| Net Non-Operating Interest Income/Expense | $4.6M | $16.6M | $19.9M | ||
| Other Income/Expense | $-405.0K | $170.0K | $78.0K | ||
| Other Special Charges | $405.0K | $-170.0K | $-78.0K | ||
| PRE-TAX INCOME | |||||
| EBIT | -- | $-252.1M | $-243.6M | ||
| Pre-Tax Income | $-130.9M | $-235.7M | $-243.6M | ||
| INCOME TAX | |||||
| Tax Provision | -- | $268.0K | $178.0K | ||
| NET INCOME | |||||
| Net Income | $-130.9M | $-235.9M | $-243.8M | ||
| Net Income (Continuing Operations) | $-130.9M | $-235.9M | $-243.8M | ||
| Net Income (Discontinued Operations) | $-130.9M | $-235.9M | $-243.8M | ||
| Net Income (Common Stockholders) | $-130.9M | $-235.9M | $-243.8M | ||
| Normalized Income | -- | $-186.2M | $-241.2M | ||
| TOTALS | |||||
| Total Expenses | $135.9M | $252.1M | $263.5M | ||
| SHARE & EPS DATA | |||||
| Average Shares Outstanding | $27.2M | $65.0M | $159.4M | ||
| Average Shares Outstanding (Diluted) | $27.2M | $65.0M | $159.4M | ||
| Shares Outstanding | $161.9M | $158.9M | $162.0M | ||
| Basic EPS | $-4.81 | $-3.63 | $-1.53 | ||
| Basic EPS (Continuing Operations) | $-4.81 | $-3.63 | $-1.53 | ||
| Diluted EPS | $-4.81 | $-3.63 | $-1.53 | ||
| Diluted EPS (Continuing Operations) | $-4.81 | $-3.63 | $-1.53 | ||
| OTHER METRICS | |||||
| Other Gand A | $31.1M | $45.5M | $62.5M | ||
| Rent And Landing Fees | -- | -- | $-3.7M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NMRA | $3.02 | +3.1% | 4.58M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Neumora Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW